Azienda Ospedaliera S. Orsola-Malpighi Trials

Azienda Ospedaliera S. Orsola-Malpighi	Welcome, Profile Billing Logout

Azienda Ospedaliera S. Orsola-Malpighi

Welcome, Profile Billing Logout

6 Trials

10 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Pantaleo, Maria Abbondanza

RAC, NCT06872853: Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District

Recruiting

N/A

1100

Europe

diagnosis, surgery, drugs for rare neoplasms

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Rare Malignant Neoplasm

11/25

12/25

NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing

N/A

Europe, Canada, US, RoW

Olaratumab, LY3012207

Eli Lilly and Company

Soft Tissue Sarcoma

Breast-Sarc, NCT04749446: Study on Clinical Features and Outcomes of Breast Sarcoma

Recruiting

N/A

300

Europe

Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)

Italian Sarcoma Group

Breast Sarcoma

12/25

ProStars, NCT06375941: Prospective Observational Study of Localized Angiosarcoma of Any Site:

Recruiting

N/A

250

Europe

Observational

Italian Sarcoma Group

Angiosarcoma

04/29

04/34

NCT02829437: Observational Study on Endometrial Stromal Tumors

Recruiting

N/A

100

Europe

Treatment for EST

Italian Sarcoma Group

Endometrial Stromal Tumors

12/25

TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting

N/A

500

Europe, RoW

Data collection and quality of life questionnaire

Centre Leon Berard

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation

06/25

SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting

N/A

4975

Europe, RoW

RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon

European Organisation for Research and Treatment of Cancer - EORTC

All Tumor Types

03/26

Nannini, Margherita

METROPHOLYS, NCT04656262 / 2018-001075-20: Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Terminated

Europe

Cyclophosphamide, Endoxan, Doxorubicin

Istituto Oncologico Veneto IRCCS, Ministry of Health, Italy

Soft Tissue Sarcoma Adult

05/24

ISG-ARTICLE, NCT04383119 / 2020-000741-13: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting

100

Europe

Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort

Italian Sarcoma Group, PharmaMar

Leiomyosarcoma of Ovary, Soft Tissue Sarcoma

12/25

NCT06863805: Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

Recruiting

N/A

Europe

4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Thyroid Carcinoma

12/26

12/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Pantaleo, Maria Abbondanza

RAC, NCT06872853: Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District

Recruiting

N/A

1100

Europe

diagnosis, surgery, drugs for rare neoplasms

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Rare Malignant Neoplasm

11/25

12/25

NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing

N/A

Europe, Canada, US, RoW

Olaratumab, LY3012207

Eli Lilly and Company

Soft Tissue Sarcoma

Breast-Sarc, NCT04749446: Study on Clinical Features and Outcomes of Breast Sarcoma

Recruiting

N/A

300

Europe

Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)

Italian Sarcoma Group

Breast Sarcoma

12/25

ProStars, NCT06375941: Prospective Observational Study of Localized Angiosarcoma of Any Site:

Recruiting

N/A

250

Europe

Observational

Italian Sarcoma Group

Angiosarcoma

04/29

04/34

NCT02829437: Observational Study on Endometrial Stromal Tumors

Recruiting

N/A

100

Europe

Treatment for EST

Italian Sarcoma Group

Endometrial Stromal Tumors

12/25

TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting

N/A

500

Europe, RoW

Data collection and quality of life questionnaire

Centre Leon Berard

06/25

SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting

N/A

4975

Europe, RoW

RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon

European Organisation for Research and Treatment of Cancer - EORTC

All Tumor Types

03/26

Nannini, Margherita

METROPHOLYS, NCT04656262 / 2018-001075-20: Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Terminated

Europe

Cyclophosphamide, Endoxan, Doxorubicin

Istituto Oncologico Veneto IRCCS, Ministry of Health, Italy

Soft Tissue Sarcoma Adult

05/24

ISG-ARTICLE, NCT04383119 / 2020-000741-13: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting

100

Europe

Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort

Italian Sarcoma Group, PharmaMar

Leiomyosarcoma of Ovary, Soft Tissue Sarcoma

12/25

NCT06863805: Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

Recruiting

N/A

Europe

4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Thyroid Carcinoma

12/26

12/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites